COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,082 Articles (22,658 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 675: Articles 6741-6750  | Next

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmed, S., Edwards, C. J., Hasdjiyiannaskis, D., Walker, L., Lyon, R., Shaw, V., Mozgunov, P., Periselneris, J., Woods, C., Bullock, K., Hale, C., Reynolds, H., Downs, N., Ewings, S., Buadi, A., Cameron, D., Edwards, T., Knox, E., Donovan-Banfield, I., Greenhalf, W., Chiong, J., Lavelle-Langham, L., Jacobs, M., Painter, W., Holman, W., Lalloo, D. G., Tetlow, M., Hiscox, J. A., Jaki, T., Fletcher, T., Griffiths, G., AGILE CST-2 Study Group
10.1101/2022.07.20.22277797 — Posted: 2022-07-24
Evaluation of Seropositivity after Standard Doses of Vaccination against SARS-CoV-2 in Early Breast Cancer Patients Receiving Adjuvant Treatment
Kim, J., Chang, E., Park, S. Y., Lee, D.-W., Kang, C. K., Choe, P. G., Kim, N. J., Oh, M.-d., Park, W. B., Lee, K.-H., Im, S.-A.
10.1101/2022.07.23.22277888 — Posted: 2022-07-24
Pin-pointing the key hubs in the IFN-gamma pathway responding to SARS-CoV-2 infection
Toro, A., Lage-Vickers, S., Bizzotto, J., Vilicich, F., Sabater, A., Pascual, G., Ledesma-Bazan, S., Sanchis, P., Ruiz, M. S., Arevalo, A. P., Porfido, J. L., Seniuk, R., Labanca, E., Anselmino, N., Navone, N., Alonso, D. F., Vazquez, E., Crispo, M., Cotignola, J., Gueron, G.
10.1101/2022.07.22.22277931 — Posted: 2022-07-23
Cervical cancer screening improvements with self- sampling during the COVID-19 pandemic
Elfström, M., Dillner, J.
10.1101/2022.07.19.22277806 — Posted: 2022-07-23
Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
Bojkova, D., Stack, R., Rothenburger, T., Kandler, J. D., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J.
10.1101/2022.07.22.501169 — Posted: 2022-07-22
COVID-19 vaccine effectiveness against mortality and risk of death from other causes after COVID-19 vaccination, the Netherlands, January 2021- January 2022
de Gier, B., van Asten, L., Boere, T., van Werkhoven, H., van Roon, A., van den Ende, C., Hahne, S., de Melker, H., Knol, M., van den Hof, S.
10.1101/2022.07.21.22277831 — Posted: 2022-07-22
Decoding the Effects of Spike Receptor Binding Domain Mutations on Antibody Escape Abilities of Omicron Variants
Chakraborty, S., Saha, A., Saha, C., Ghosh, S., Mondal, T.
10.1101/2022.07.21.500931 — Posted: 2022-07-22
Suppression of systemic T cell immunity to viral infection during liver injury is prevented by inhibition of interferon and IL-10 signaling
Hackstein, P. C., Spitzer, J., Symeonidis, K., Horvatic, H., Bedke, T., Steglich, B., Assmus, L., Odainic, A., Kessler, N., Klein, S., Beyer, M., Schmithausen, R., Latz, E., Kurts, C., Trebicka, J., Flavell, R., Garbi, N., Roers, A., Huber, S., Schmidt, S., Knolle, P., Abdullah, Z.
10.1101/2022.07.21.501031 — Posted: 2022-07-22
Learning from pre-pandemic data to forecast viral antibody escape
Thadani, N. N., Gurev, S., Notin, P., Youssef, N., Rollins, N. J., Sander, C., Gal, Y., Marks, D.
10.1101/2022.07.21.501023 — Posted: 2022-07-22
Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
QU, P., Faraone, J. N., Evans, J. P., Zheng, Y.-M., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., Liu, S.-L.
10.1101/2022.07.21.501010 — Posted: 2022-07-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).